Mylan deal may skirt new IRS/Treasury inversion rules

Some unknowns loom but Pittsburgh-area pharmaceuticals company Mylan Inc.’s pending inversion deal appears poised to glide past new measures by the Obama administration to curb such transactions, analysts believe...